Published online Aug 15, 2023. doi: 10.4251/wjgo.v15.i8.1349
Peer-review started: January 14, 2023
First decision: March 14, 2023
Revised: March 29, 2023
Accepted: June 25, 2023
Article in press: June 25, 2023
Published online: August 15, 2023
Processing time: 207 Days and 18.8 Hours
There is an intimate crosstalk between cancer formation, dissemination, treatment response and the host immune system, with inducing tumour cell death the ultimate therapeutic goal for most anti-cancer treatments. However, inducing a purposeful synergistic response between conventional therapies and the immune system remains evasive. The release of damage associated molecular patterns (DAMPs) is indicative of immunogenic cell death and propagation of established immune responses. However, there is a gap in the literature regarding the impor
To investigate the effects of conventional therapies on DAMP expression and to determine whether OAC is an immunogenic cancer.
We investigated the levels of immunogenic cell death-associated DAMPs, calreticulin (CRT) and HMGB1 using an OAC isogenic model of radioresistance. DAMP expression was also assessed directly using ex vivo cancer patient T cells (n = 10) and within tumour biopsies (n = 9) both pre and post-treatment with clinically relevant chemo(radio)therapeutics.
Hypoxia in combination with nutrient deprivation significantly reduces DAMP expression by OAC cells in vitro. Significantly increased frequencies of T cell DAMP expression in OAC patients were observed following chemo
In conclusion, OAC expresses an immunogenic phenotype with two distinct subgroups of high and low DAMP expressors, which correlated with tumour regression grade and lymphatic invasion. It also identifies DAMPs namely CRT and HMGB1 as potential promising biomarkers in predicting good pathological responses to conventional chemo(radio)therapies currently used in the multimodal management of locally advanced disease.
Core Tip: The purpose of this study was to investigate the effects of conventional therapies on damage associated molecular patterns expression and we determined oesophageal adenocarcinoma is an immunogenic cancer and is a viable target for immunotherapeutics.
